Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 17/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 17/20 | 0.63 |
| ▸ | HRH1 | P35367 | 4/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.63 |
| ▸ | HRH2 | P25021 | 3/20 | 0.63 |
| ▸ | HTR1A | P08908 | 2/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.63 |
| ▸ | DRD1 | P21728 | 1/20 | 0.63 |
| ▸ | HTR1B | P28222 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 1/20 | 0.63 |
| ▸ | HTR1E | P28566 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.63 |
| ▸ | HTR2B | P41595 | 1/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1793928 | 0.90 | TMEM97 (0.67) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL1027550 | 0.90 | TMEM97 (0.67) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL20570718 | 0.90 | TMEM97 (0.61) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL2281885 | 0.87 | TMEM97 (0.61) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL21800344 | 0.86 | TMEM97 (0.66) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL324086 | 0.85 | TMEM97 (0.64) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL1506610 | 0.84 | TMEM97 (0.63) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL1017246 | 0.84 | TMEM97 (0.63) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL31129893 | 0.84 | TMEM97 (0.63) | TMEM97SIGMAR1HRH1HRH3HRH2 | |
| SCHEMBL29469365 | 0.84 | TMEM97 (0.63) | TMEM97SIGMAR1HRH1HRH3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414435-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20200317698-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-10-08 | — | — | US | disclosed |
| US-10450301-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| EP-2943204-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-20180362503-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-12-20 | — | — | US | disclosed |
| WO-2018218051-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| US-10125152-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| US-10093685-B2 | — | — | 2018-10-09 | — | — | US | disclosed |
| US-20170342093-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-30 | — | — | US | disclosed |
| US-9771382-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-09-26 | — | — | US | disclosed |
| US-8575193-B2 | N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2013-11-05 | — | — | US | disclosed |
| US-8575193-B2 | N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20110201643-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201643-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201643-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2274283-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009112550-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112550-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2009-09-17 | — | — | WO | disclosed |
| EP-2100879-A1 | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2009-09-16 | — | — | EP | disclosed |
| EP-2100879-A1 | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342093-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | TMEM97 4099/4885SIGMAR1 3058/4885HRH1 3954/4885 |
| US-10093685-B2 | — | MRPL21, GAA, MGAM | TMEM97 3723/4885SIGMAR1 2343/4885HRH1 4056/4885 |
| US-20180362503-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, AIFM1, BCL2 | TMEM97 2280/4885SIGMAR1 1703/4885HRH1 4510/4885 |
| US-10125152-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | TMEM97 4099/4885SIGMAR1 3058/4885HRH1 3954/4885 |
| US-20200317698-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | TMEM97 4099/4885SIGMAR1 3058/4885HRH1 3954/4885 |
| US-10450301-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, AIFM1, BCL2 | TMEM97 2280/4885SIGMAR1 1703/4885HRH1 4510/4885 |
| US-11414435-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | TMEM97 4099/4885SIGMAR1 3058/4885HRH1 3954/4885 |
| US-20110201643-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | HDAC1, HDAC3, HDAC4 | TMEM97 3168/4885SIGMAR1 1674/4885HRH1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.